Ministero della Salute

1 Ministero della SaluteDirezione Generale della Ricerca e dell' Innovazione in Sanit BANDO RICERCA FINALIZZATA 2016 GRADUATORIA SEZIONE ORDINARIA RFCriteri Sub RankingRANKC odiceProgettoTipo RicercaTitolo ProgettoDISCORE FINALER ispondenza RilenvanzaQualit ScientificaChiarezza e AppropiatezzaTrasferibilit nel SSNCVS core Impatto ) Theory enhancing:Targeting the tumor vasculature with TNF bearing nanoparticles tagged with a non deamidating NGR peptideSAN RAFFAELE MILANO15,5011,51,51,531RF 2016 023610546,008,502a) Theory enhancing:The FEDRA (Florence EPIC Digital mammographic density and breast cancer Risk Assessment) Study: Determinants of mammographic breast density and breast cancer risk in a large cohort of women with repeated breast density measurements based on full field digToscana15,50132,51,521RF 2016 023647458,506,003a) Theory enhancing:Does exercise training mostly unmask congenital long QT syndrome or simply reveals a novel form of acquired long QT syndrome in genetically predisposed youngsters practicing sports?

2 Ethical and medical implications of a potentially dangerous ,50222,521,51RF 2016 023615018,006,504a) Theory enhancing:Biological basis for Zika virus induced severe complications: impact on prevention strategiesSPALLANZANI15,751222,521RF 2016 023641558,506,255c) Change promoting:Italian Rare Cancer Network: Process monitoring and System impact TUMORI MILANO16,0011,7522,2513RF 2016 023633867,505,50 Pagina 1 di 94 Bando Ricerca Finalizzata 2016 Graduatoria Sezione Ordinaria RFCriteri Sub RankingRANKC odiceProgettoTipo RicercaTitolo ProgettoDISCORE FINALER ispondenza RilenvanzaQualit ScientificaChiarezza e AppropiatezzaTrasferibilit nel SSNCVS core Impatto ) Change promoting:Efficacy and tolerability of low vs.

3 Standard daily doses of antiepileptic drugs in newly diagnosed, previously untreated epilepsy. A multicenter, randomized, single blind, parallel group trialMARIO NEGRI16,0022,51113RF 2016 023639027,505,507a) Theory enhancing:Characterization of the RBX1 E3 ligase as a negative regulator of the tumor suppressor Numb and target for anti cancer stem cell therapies in Numb deficient breast ,2512,52,522,751RF 2016 023615409,007,258a) Theory enhancing:Intestinal microbiome biomarkers for non celiac gluten sensitivity: new diagnostic and therapeutic Romagna17,2521,51,51,52,751RF 2016 023648145,5010,759b) Change promoting:Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS BALANCED trial).

4 A 2 by 2 factorial, investigator initiated, open label, multicenter, randomized, controlled ,00222,52,521RF 2016 023615839,008,0010b) Change promoting:The Pediatric Autoimmunity and Diabetes (PAD) Project: towards an optimal use of public resources in Diabetes CareSAN RAFFAELE MILANO18,25132,531,252RF 2016 0236407011,504,7511a) Theory enhancing:Repositioning of Niacin/Nicotinic acid for the therapy of CMT neuropathies with focal hypermyelinationSAN RAFFAELE MILANO18,5012,52,5222RF 2016 023612469,007,5012a) Theory enhancing:Precision medicine to study and prevent metabolic adverse effects induced by second generation antipsychotic drugs: pharmacogenetic profiling in patients and mechanistic analysis of the effect of genetic variants in vitroLombardia18,7511,51,522,753RF 2016 023637616,509,25 Pagina 2 di 94 Bando Ricerca Finalizzata 2016 Graduatoria Sezione Ordinaria RFCriteri Sub RankingRANKC odiceProgettoTipo RicercaTitolo ProgettoDISCORE FINALER ispondenza RilenvanzaQualit ScientificaChiarezza e AppropiatezzaTrasferibilit nel SSNCVS core Impatto ) Theory enhancing.

5 Identification of new biomarkers for Oligoarticular Juvenile Idiopathic Arthritis by exosomal miRNA assessment in blood and synovial fluid GASLINI19,0011,5222,54RF 2016 023610487,008,0014b) Change promoting:Design of new personalized therapeutic approaches for diffuse large B cell lymphomaEmilia Romagna19,00112,52,52,754RF 2016 023637307,008,0015a) Theory enhancing:Impact of different treatment strategies on clonal evolution in multiple myelomaEmilia Romagna19,0012,5322,52RF 2016 023625329,507,5016a) Theory enhancing:Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras mutated metastaTIc cOlorectal caNcer (REVOLUTION trial)PASCALE19,0013331,51RF 2016 0236331412,006,0017a) Theory enhancing:Development of an Italian clinical/diagnostic network focused on the prevention and management of virologic failures in hepatitis C virus (HCV) patients treated with direct antivirals agents (DAAs)Sicilia19,0021,5222,52RF 2016 023624227,0010,0018a) Theory enhancing.

6 Dissecting the link between pulmonary stromal changes and lung cancer progression for biomarkers discovery and therapeutic interventionISTITUTO TUMORI MILANO19,00222223RF 2016 023629468,008,0019a) Theory enhancing:Translational genetics of hereditary dysmyelinating disorders of the central nervous system: deep phenotyping, NGS strategies, and model organisms for clinical diagnosis and identification of novel disease genesCARLO BESTA19,2511,52,51,53,52RF 2016 023612857,0010,25 Pagina 3 di 94 Bando Ricerca Finalizzata 2016 Graduatoria Sezione Ordinaria RFCriteri Sub RankingRANKC odiceProgettoTipo RicercaTitolo ProgettoDISCORE FINALER ispondenza RilenvanzaQualit ScientificaChiarezza e AppropiatezzaTrasferibilit nel SSNCVS core Impatto ) Theory enhancing:Interplay between gut microbiota and adaptive immunity in Amyotrophic Lateral Sclerosis: a clinical trialEmilia Romagna19,2512,52,52,52,53RF 2016 023616169,007,2521a) Theory enhancing.

7 Mitophagy and autophagy in the ischemic brain: a new target to promote neuroprotectionSAN RAFFAELE MILANO19,2512323,251RF 2016 023615718,509,7522b) Change promoting:Anti nerve reactivity as predictor of response to immune therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)HUMANITAS19,5011,521,51,57RF 2016 023618877,505,0023a) Theory enhancing:Efficacy assesment of new targeted combination therapies for muscoloskeletal sarcomas as the basis for tailoring patient's treatmentRIZZOLI19,5012222,54RF 2016 023613738,007,5024a) Theory enhancing:Adoptive immunotherapies with regulatory and conventional T cells and/or Natural Killer cells: safe and effective strategies to minimize the risk of leukemia relapse after allogeneic hematopoietic stem cell ,5011,52,52,523RF 2016 023643838,008,5025c) Change promoting:Basic requirements and preliminary studies for a program of prevention of diabetes type 2 in ,00122223RF 2016 023645138,508,5026b) Change promoting:Impact of whole exome sequencing on the clinical management of patients with advanced nonalcoholic fatty liver and cryptogenic liver disease MAGGIORE20,00122231RF 2016 023643588,0011,0027b) Change promoting.

8 First in human Italian Phase I II Trial based on adoptive Chimeric Antigen receptor (CAR) T cells specific for GD2 antigen in patients with high risk neuroblastoma. OSPEDALE BAMBINO GESU'20,00222,52,531RF 2016 023643889,0010,00 Pagina 4 di 94 Bando Ricerca Finalizzata 2016 Graduatoria Sezione Ordinaria RFCriteri Sub RankingRANKC odiceProgettoTipo RicercaTitolo ProgettoDISCORE FINALER ispondenza RilenvanzaQualit ScientificaChiarezza e AppropiatezzaTrasferibilit nel SSNCVS core Impatto ) Theory enhancing:MUSE: understanding the Mechanisms Underlying the Selection and spread of carbapenem resistant Enterobacteriaceae in intensive care units.

9 A multicenter clinical epidemiological study coupled with molecular ,50132,5314RF 2016 0236458410,506,0029a) Theory enhancing:Combined electroclinical and morpho functional analysis for the identification, definition, and surgical removal of the human epileptogenic zone in drug resistant patientsCARLO BESTA20,50132,53,51,55RF 2016 0236219511,004,5030a) Theory enhancing:Lipid metabolism network as a target to overcome resistance in melanomaISTITUTO TUMORI MILANO20,75122,532,753RF 2016 023610919,508,2531a) Theory enhancing:Addressing residual challenges of HCV infection in the era of Direct Acting Antiviral (DAAs) therapies : co morbidities, gender differences, universal access.

10 Translation of clinical findings from large national cohorts into health care ,751,52,53,53,52,53RF 2016 0236405311,006,7532a) Theory enhancing:Role of the adipokine visfatin in inflammation and metabolic syndromesHUMANITAS20,75222,523,51RF 2016 023648428,5011,2533a) Theory enhancing:Transition metal ions as a new therapeutic target for cardiac light chain MATTEO21,00122136RF 2016 023617566,009,0034a) Theory enhancing:Multimodal nanotracking for exosome based therapy in DMDMAGGIORE21,001,522,5244RF 2016 023622638,009,0035a) Theory enhancing:Circulating levels of hydrohen sulfide (H2S) as a novel marker of bone turnover in postmenopausal osteoporosis and agingToscana21,001,51,531,53,253RF 2016 023622387,5010,50 Pagina 5 di 94 Bando Ricerca Finalizzata 2016 Graduatoria Sezione Ordinaria RFCriteri Sub RankingRANKC odiceProgettoTipo RicercaTitolo ProgettoDISCORE FINALER ispondenza RilenvanzaQualit ScientificaChiarezza e AppropiatezzaTrasferibilit nel SSNCVS core Impatto ) Theory enhancing.